- New Chief Medical Officer will play a major role in defining best paths to adoption, clinical strategies, and partnerships
- Dr. Fitzgerald serves as director of the Center for Cardiovascular Technology and of the Cardiovascular Core Analysis Laboratory at Stanford University Medical School
- Dr. Fitzgerald brings impressive expertise in the clinical, research and industry sectors
In a display of its commitment to offering innovative, high-quality products and services, cardiac tech company HeartBeam (NASDAQ: BEAT) has named a world-renowned interventional cardiologist with an impressive breadth of experience as its Chief Medical Officer (https://ibn.fm/pN1kf). Stanford cardiologist Peter J. Fitzgerald, MD, PhD, will help HeartBeam continue to develop the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere.
“We are thrilled to have Dr. Fitzgerald, one of the world’s preeminent opinion leaders in cardiology and digital health, join the HeartBeam leadership team and play a major role in defining best paths to adoption, clinical strategies, and partnerships to advance our products in the market,” said HeartBeam founder and CEO Branislav Vajdic, PhD. “In addition to his cardiovascular clinical and research expertise, Dr. Fitzgerald has a rich history of developing successful collaborations with partners in the industry and has developed deep connections across the investment and medical communities.”
Dr. Fitzgerald joins HeartBeam after gaining invaluable experience in the clinical, research and industry sectors. An accomplished inventor, entrepreneur, and investment-fund founder, Dr. Fitzgerald is serving as director of the Center for Cardiovascular Technology and director of the Cardiovascular Core Analysis Laboratory at Stanford University Medical School.
He is a professor emeritus from the Department of Medicine (Cardiology) at Stanford University and has been integrally involved in more than 175 clinical trials. His expertise as an author is profound, with more than 650 manuscripts or chapters to his name. He is also a prominent speaker and trainer, having lectured around the world and trained more than 150 post-doctoral candidates in engineering and medicine.
Outside of the academic world, Dr. Fitzgerald has been principal and founder of 24 medical-device companies, leading 18 of those from start-up stage to becoming medium-cap or large-cap life-science companies. In addition, he cofounded Israeli-based TriVentures, an incubator/venture fund targeting early-stage medical technology and digital health. Finally, for the past two decades, Dr. Fitzgerald has served as a consultant to the U.S. Food and Drug Administration (“FDA”), where his focus has been on medical technology and data-driven health analytics.
With his PhD in electrical engineering and extensive background, Dr. Fitzgerald is imminently qualified for his new position. “HeartBeam’s focus on bringing novel diagnostic tools to cardiac patients, especially those with a high risk for a heart attack, could have a significant, positive impact on medical outcomes and quality of life for patients while potentially saving healthcare dollars,” said Dr. Fitzgerald. “I look forward to supporting the planned advancement of the Company’s rich product pipeline to deliver comprehensive cardiac care for patients anytime, anywhere.”
HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to quickly and easily determine if symptoms are due to a heart attack so care can be expedited, if required. HeartBeam has two patented products in development: HeartBeam AIMI(TM) is software for acute-care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack more accurately. HeartBeam AIMIGo(TM) is the first and only credit-card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system to facilitate remote heart attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the FDA for marketing in the USA or other geographies.
For more information, visit the company’s website at www.HeartBeam.com.
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com